Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 24,400 KRW
Change Today +1,150 / 4.95%
Volume 118.9K
016580 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:15 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

whanin pharmaceutical co ltd (016580) Snapshot

Open
23,100
Previous Close
23,250
Day High
24,400
Day Low
22,650
52 Week High
10/22/14 - 28,100
52 Week Low
08/5/14 - 14,300
Market Cap
453.8B
Average Volume 10 Days
153.4K
EPS TTM
1,150
Shares Outstanding
18.6M
EX-Date
12/29/14
P/E TM
21.2x
Dividend
250.00
Dividend Yield
1.02%
Current Stock Chart for WHANIN PHARMACEUTICAL CO LTD (016580)

Related News

No related news articles were found.

whanin pharmaceutical co ltd (016580) Related Businessweek News

No Related Businessweek News Found

whanin pharmaceutical co ltd (016580) Details

Whanin Pharmaceutical Co., Ltd., a pharmaceutical company, develops, manufactures, markets, and sells therapeutic products in South Korea. The company offers its products in various therapeutic categories, such as antiasthmatics, antidepressants, antipsychotics, anxiolytics and hypnotics, antiepileptic, ADHD agents, alcoholism treatment, nootropics, antiparkinson drugs, antidementia drugs, gastrointestinal drugs, cardiovascular drugs, osteoporosis treatment, immunostimulating agents, anti-inflammatory analgesics, erectile dysfunction treatment, antibiotics, multi-vitamins, antihaemorrhoids, antidiabetic agents, respiratory drugs, antifungal, antihistamines, dermatological, and antiviral. Its pipeline under development include WIN-901X, which is in Phase II completed stage for asthma indication; WIB-801C, a pre-clinical trial completed product for stroke indication; and WIN902A, a pre-clinical trial completed product for treating obesity, as well as evaluation stage products comprising WIB-1001C for treating dementia and HCV for treating hepatitis C type. The company was founded in 1978 and is headquartered in Seoul, South Korea.

416 Employees
Last Reported Date: 11/13/13
Founded in 1978

whanin pharmaceutical co ltd (016580) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

whanin pharmaceutical co ltd (016580) Key Developments

Whanin Pharmaceutical Co. Ltd., Annual General Meeting, Mar 20, 2015

Whanin Pharmaceutical Co. Ltd., Annual General Meeting, Mar 20, 2015., at 10:00 Korea Standard Time. Location: 4 great way to Seoul Songpa-gu, Songpa 4 Youth Center 3rd floor. Agenda: To consider the financial Statements; to consider the some changes to the Articles of Incorporation of the cases; to consider the appointment of Director; to consider the remuneration ceiling; and to consider regulatory Approval of executive severance pay.

Whanin Pharmaceutical Co. Ltd., Annual General Meeting, Mar 14, 2014

Whanin Pharmaceutical Co. Ltd., Annual General Meeting, Mar 14, 2014., at 10:00 Korea Standard Time. Location: 4 Songpa-dong, Songpa-gu. Agenda: To approve audit reports and sales reports; to approve incorporation of some changes; to approve appointment of outside directors; to approve appointment of Audit Committee; and to consider approval of directors' remuneration limit.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
016580:KS 24,400.00 KRW +1,150

016580 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 016580.
View Industry Companies
 

Industry Analysis

016580

Industry Average

Valuation 016580 Industry Range
Price/Earnings 23.2x
Price/Sales 3.3x
Price/Book 2.0x
Price/Cash Flow 28.3x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WHANIN PHARMACEUTICAL CO LTD, please visit www.whanin.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.